AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06214377 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The Starstim tCS® equipment (Neuroelectrics Inc, Barcelona, Spain) will be used with 35 cm2 sponge electrodes. The tDCS sham over M1 will be performed by placing the electrodes in the same position as in the active tDCS protocol. However, the stimulator will automatically turn off after 30 seconds of stimulation, making it a reliable sham stimulation method. Therefore, subjects will feel the same tingling sensation but will not receive current for the remainder of the stimulation time.
Study NCT06214377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Direct Current Stimulation
Description: The Starstim tCS® equipment (Neuroelectrics Inc, Barcelona, Spain) will be used with 35 cm2 sponge electrodes. The tDCS sham over M1 will be performed by placing the electrodes in the same position as in the active tDCS protocol. However, the stimulator will automatically turn off after 30 seconds of stimulation, making it a reliable sham stimulation method. Therefore, subjects will feel the same tingling sensation but will not receive current for the remainder of the stimulation time.
Study NCT06214377 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dopaminergic medication
Description: After tDCS, the participant will take their regular dopaminergic medication in order to go from OFF state to ON state.
Study NCT06214377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication
Description: After tDCS, the participant will take their regular dopaminergic medication in order to go from OFF state to ON state.
Study NCT05348109 — intervention group
Intervention type: OTHER
Intervention: Well finished cases
Description: To decide whether extraction or non-extraction decision will be made for each case
Study NCT05418348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-104
Description: new formulation of nimodipine injection for IV infusion
Study NCT05418348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine Capsules
Description: Nimodipine capsules (reference formulation)
Study NCT06394102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The automatic color temperature adjustment mode equipped on terminal display devices can reduce the discrepancy between the color temperature of the device and the ambient light.
Description: A program mode on a terminal display device that reduces the difference between the color temperature of the ambient light and that of the display device.
Study NCT04933513 — intervention group
Intervention type: BEHAVIORAL
Intervention: pre DBS patients responding to the DBS-PS scale
Description: we propose to parkinson's disease patients selected for subthalamic deep brain stimulation to complete the DBS-PS scale preoperatively
Study NCT04747249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological support
Description: Psychological care will be based on a monthly interview lasting approximately 45 minutes for 6 months.
Study NCT05033925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FADA (active fraction of Ficus septica leaf) 800 mg/day
Description: FADA is given twice a day (total dose of 800 per day per patient)
Study NCT05033925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FADA (active fraction of Ficus septica leaf) 2000 mg/day
Description: FADA is given twice a day (total dose of 2000 per day per patient)
Study NCT05033925 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule is given twice a day
Study NCT06391359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study NCT06391359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watchful waiting
Description: Watchful waiting
Study NCT05084183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PermeaDerm®
Description: Wound Management Device
Study NCT05084183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Ag
Description: Wound Dressing
Study NCT06338397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCANN
Description: Administering 11 tests of social \& affective cognition to each participant as well as 6 scales to their study-partner, in order to have a detailed profile of social \& affective cognitive abilities that we can correlate to an 3DMRI with resting state procedure.
Study NCT04332003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC) Treatment
Description: RIC treatment will be delivered by an automated device that delivers the RIC treatment (manufactured by LifeCuff Technologies).
Study NCT05909267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa/Carbidopa
Description: Patients and healthy controls will receive one time administration of L-dopa/Carbidopa (100/25 mg).
Study NCT05909267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients and healthy controls will receive one time administration of Placebo.
Study NCT06454006 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT-sMF
Description: Placebo, without therapeutic dose.
Study NCT06454006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active PBMT-sMF
Description: Active with a dose of 31.50 J per site.
Study NCT06455020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Emergency catheter ablation is defined as ablation performed within 48 hours of hospital admission
Study NCT06455020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepped-care strategies
Description: Patients randomized to the stepped-care strategy arm will receive treatment through a systematic, stepwise protocol beginning with anti-arrhythmic drugs, followed by sedation and anesthesia, and progressing to haemodynamic mechanical support devices if earlier treatments prove ineffective. Catheter ablation will be reserved as the final rescue intervention.
Study NCT05945199 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: * 1 session/day for 5 consecutive days~* stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group
Study NCT05945199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: * 1 session/day for 5 consecutive days~* stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group
Study NCT05945199 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of risk behaviours
Description: Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)
Study NCT05945199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of risk behaviours
Description: Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)
Study NCT05945199 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scales
Description: EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II
Study NCT05945199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scales
Description: EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II
Study NCT05522010 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical spine surgery
Description: A standard anterior approach was made with discectomy sparing the cartilage, and with foraminal decompression. Complete excision of the posterior longitudinal ligament was routinely performed to complete neural decompression. Trial inserters were used to identify the proper implant size. Device under sizing may lead to poor ﬁxation and implant migration. The largest possible device that can be safely placed should be selected to maximize device- endplate contact and to gain support from the apophyseal rim. The teeth of the implant were optimally ﬁxated to the endplate via Caspar pin compression following device insertion. The device may be replaced or changed using the same insertion instrument if ﬁnal imaging demonstrated suboptimal positioning. Rinsing the implanted disc space removes rests of blood and bone dust, all potentially promoting HO
Study NCT05258253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity aerobics
Description: London bridges (8mins) Jumping lunges(8mins) Mountain climbers(8mins) Quadruped bent knee hip extension (8mins)
Study NCT05258253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic clock exercises
Description: Lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Subject begin with gentle movements from 12 to 6 o'clock, as instructed to move from 3 o'clock to 9 o'clock. Then move in a clockwise manner from 12 to 3 to 6 to 9 and then back to 12 o' clock.
Study NCT05907798 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: LIMA Blood flow
Description: 30 minutes after induction
Study NCT05907798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIMA Blood flow
Description: 30 minutes after induction
Study NCT05806606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dyadic empowerment based heart failure management program
Description: The 16-week De-HF Program is delivered on a dyadic basis, The program consists of three core elements: i) joint dyadic interview in a home visit (1st-2nd week), ii) five ICT-enhanced empowerment-based modules (3rd-12th week; 2 sessions/ each module), and iii) post-module telephone follow-up (13th-16th week). The overall aim of the dyadic interview is to understand their usual pattern of collaboration, deficits, strengths and competing concerns in disease management. This is followed by the empowerment modules with the purpose to help the care dyads to get a consensus in disease interpretation (1st session: Perceptual and Cognitive Empowerment Session) and develop collaborative goal attainment process (2nd Session: Collaborative Gaol-Setting Process). This will be followed by two bi-weekly telephone calls to the care dyads using a speaker phone to monitor their level of goal attainment for the five modules, and to give further advice and counselling.
Study NCT05806606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dyadic education program
Description: The 16-week HF education program comprises a home visit, five bi-weekly online training sessions, and the subsequent telephone follow-up for the care dyads. The nurse will first assess how they manage HF in terms of medication compliance, fluid and dietary control, symptom monitoring and responses in a home visit and clarify their major misconceptions in self-care. This will be followed by five bi-weekly online education sessions on the same topics as the empowerment modules in the De-HF program.
Study NCT06042309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rubber accelerators and control chamber/solution for NON-SLS group
Description: Repeated exposure to rubber accelerators and control chamber/solution on arms. Three different concentrations of rubber accelerators and one control chamber/solution will be applied on the arms.
Study NCT01351090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 10 mg Intranasal (2 x 100 uL of a 5% solution)
Study NCT01351090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 30 mg Intranasal (2 x 100 uL of a 15% solution)
Study NCT01351090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal
Study NCT05454995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vessel Restoration System (VRS)
Description: Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)
Study NCT04724603 — intervention group
Intervention type: OTHER
Intervention: patients having had avderse event after phagotherapy for bone or joint or implant infection
Description: to determine the accountability of adverse effects in having had avderse event after phagotherapy for bone or joint or implant infection
Study NCT04878055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: 2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).
Study NCT04878055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo, i.e. 2 tablets for the total of three daily administrations (6 tablets daily).
Study NCT05258734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVOS app
Description: In this study, the patients in the experimental group will be followed up with the COVOS app and nursing interventions (videos, information messages) to manage their symptoms will be directed with the COVOS app.
Study NCT05258734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: In this study, the patients in the control group will not receive any intervention, the standard follow-up and health care provided by the family health center of the patients will continue.
Study NCT03972384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-ICU Problem Solving
Description: We have adapted the Cognitive Orientation to Daily Occupational Performance (CO-OP) as the Post-ICU Problem Solving intervention to be delivered in the home to patients following an illness that required an ICU stay. CO-OP is a form of meta-cognitive strategy training that teaches individuals to identify and prioritize problematic daily activities, identify barriers impeding performance, generate and evaluate strategies addressing these barriers, and generalize learning through practice. Thus, strategy training teaches skills that can be used to address disability in real-life activities, and is integral to personalized rehabilitation services. CO-OP has been adapted in numerous settings and most recently, it is being utilized successfully in patients with acquired cognitive dysfunction following acute stroke. This represents a useful intervention, tested in similar populations with minimal risk to the participants and potential for maximal benefit for this population.
Study NCT05684289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days
Study NCT05684289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Specified dose on specified days
Study NCT05684289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: Specified dose on specified days
Study NCT05684289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT06042309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLS
Description: Exposure to SLS on a randomized arm
Study NCT06042309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rubber accelerators and control chamber/solution for SLS group
Description: Repeated exposure to rubber accelerators and control chamber/solution on arms. Two different concentrations of rubber accelerators and one control chamber/solution will be applied on both arms.
Study NCT06042309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch test on back
Description: Patch test on the back with thiurams or carbamates in different concentrations and a control chamber/solution
Study NCT06208527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR)
Description: A total of 2000 mg NR is administered daily for 1 year.
Study NCT05063578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Description: Different concentration of lidocaine, injected via axillary block for arterio-venous fistula creation surgery
Study NCT06208527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet identical in taste, shape and appearance to NR tablets.
Study NCT06169306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: throat pack
Description: Following endotracheal intubation, one saline soaked, throat pack will inserted into the hypopharynx under direct vision. The packs will record in writting on the anaesthesia safety form.
Study NCT06445322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prescreening Assessments
Description: Various genetic and visual assessments.
Study NCT06446661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity
Description: Daily texts
Study NCT06446661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Text Messagings
Description: Standard Care
Study NCT06446661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Text Messaging
Description: Weekly Texts
Study NCT04952129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenomethionine
Description: Seleno-amino acid
Study NCT04952129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylselenocysteine
Description: Seleno-amino acid
Study NCT06360328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscopy
Description: The residents used video laryngoscopy for endotracheal intubation
Study NCT04691817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200mg infusion
Study NCT04691817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 6mg/kg or 4mg/kg infusion
Study NCT05562752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: multistrain probiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 12 weeks.
Study NCT05562752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in a form of a capsule for 12 weeks.
Study NCT06434675 — intervention group
Intervention type: OTHER
Intervention: No intervention done
Description: No intervention done
Study NCT06405178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Insulin Sensitizer
Study NCT06405178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Sodium-Glucose Co-transporter-2
Study NCT06405178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: Anti diabetic drug
Study NCT06405178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromataze inhibitor
Study NCT06008054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: Administered by intravenous infusion every 3 weeks (Q3W).
Study NCT06008054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administered by intravenous infusion for a cycle of 3 weeks.
Study NCT06008054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT06404749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fungal fiber
Description: fungal fiber from mycelium
Study NCT06404749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: inulin
Description: long chain, degree of polymerization DP>23
Study NCT04719598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: congnitive behavioural therapy
Description: CBT Sessions divide into three main components; 1) cognitive interventions, concerns with cognitive restructuring attempts to change maladaptive thought about thoughts about sleep into more adaptable . 2) Behavioral intervention: concerns with Relaxation training, stimulus control, and sleep restriction promote relaxation and help to establish healthy sleep habits. 3) Psychoeducational interventions: Providing information about the connection between thoughts, feelings, behaviors, and sleep.
Study NCT05288946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local segmental control and closed kinetic chain
Description: the patients will receive Lumbar multifidus activation and Transversus abdominis activation then closed kinetic chain exercise in the form of Stand-up position on unstable surface, Closed chain lunge exercises, with the addition of hand weights, Bridge in prone position, Bridge in supine position, Lateral Bridge
Study NCT05288946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local segmental control and open kinetic chain
Description: the patients will receive Lumbar multifidus activation and Transversus abdominis activation then open kinetic chain in the form of Lower limb abduction, Knee extension in a supine position on a roller, Open chain exercise of the upper limb after co-contraction of transversus abdominis and multifidus.